Risk of hepatocellular carcinoma in untreated patients with chronic hepatitis B: Independent of HBeAg status?

키워드

참고문헌 (9)

1. Korean Association for the Study of the Liver (KASL), "KASL clinical practice guidelines for management of chronic hepatitis B", Clinical and Molecular Hepatology, 25(2), pp.93~159 (2019), 대한간학회
2. Kim GA, "High risk of hepatocellular carcinoma and death in patients with immunetolerant-phase chronic hepatitis B", Gut, 67, pp.945~952 (2018)
3. Sinn DH, "Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load", Hepatology, 62, pp.694~701 (2015)
4. Kim GA, "Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients", Aliment Pharmacol Ther, 51, pp.1169~1179 (2020)
5. Choi GH, "High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation", Aliment Pharmacol Ther, 50, pp.215~226 (2019)
6. Lilian Yan Liang, "Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B", Clinical and Molecular Hepatology, 27(3), pp.499~509 (2021), 대한간학회[DOI]
7. Wong VW, "Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers", J Clin Oncol, 28, pp.1660~1665 (2010)
8. Yuen MF, "Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B", J Hepatol, 50, pp.80~88 (2009)
9. Yang HI, "Risk estimation for hepatocellular carcinoma in chronic hepatitis B(REACHB) : development and validation of a predictive score", Lancet Oncol, 12, pp.568~574 (2011)

관련 논문AI추천